IP Library Granted Patent US 10,385,099
Granted Patent B2
US 10,385,099 · App. 14/962,952 · Granted Aug 20, 2019

Cyclic amino acid molecules and methods of preparing the same

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,385,099
App. No.
14/962,952
Granted
Aug 20, 2019
Kind
B2
Abstract

Macrocyclization of amino acids or linear peptides upon reaction with amphoteric amino aldehydes and isocyanides is provided.

Claims (32)

1. A cyclic compound of formula (III)

wherein

n=0 or 1, and R1, R2, R3, R4 and R5 are independently selected from H; lower alkyl; aryl; heteroaryl; alkenyl; heterocycle; cyckoalkyl; esters of the formula C(O)OR* wherein R* is selected from alkyl and aryl; amides of the formula C(O)NR**R***, wherein R** and R*** are independently selected from alkyl and aryl; —CH 2 C(O)R, wherein R is selected from —OH, lower alkyl, aryl, -lower alkyl-aryl, or —NR a R b , where R a and R b are independently selected from H, lower alkyl, aryl or -lower alkyl-aryl; —C(O)R c , wherein R c is selected from lower alkyl, aryl or -lower alkyl-aryl; or -lower alkyl-OR d , wherein R d is a suitable protecting group or OH group;

bonds [a] and [b] are syn or antito each other;

R′ is an amino acid side chain of the amino terminus amino acid;

R″ is an optionally substituted amide; and

R 6 is a nucleophilic moiety of a compound having the formula R 6 —H, wherein R 6 —H is selected from the group consisting of 7-mercapto-4-methyl-coumarin, thiobenzoic acid, thioacetic acid, biotin, aromatic thiols, aliphatic thiols; and is capable of nucleophilic opening of the aziridine ring of a compound of formula (II)

to form the compound of formula (III);

and the linear molecule is an amino acid, a linear peptide comprising 2-9 amino acids, or a salt of the amino acid or the linear peptide, wherein N′ is the nitrogen at the amino terminus end of the linear molecule and C′ is the carbon at the carboxy terminus end of the linear molecule, and provided that if the linear molecule is a linear peptide, bonds [a] and [c] are anti—to each other.

2. The cyclic compound of claim 1 , wherein R 6 is a fluorescent moiety.

3. The cyclic compound of claim 1 , wherein any one of R 1 -R5 is H.

4. The cyclic compound of claim 1 , wherein n=0 and R 1 -R 3 are H.

5. The cyclic compound of claim 3 , wherein n=0 and R 2 and R 3 are H.

6. The cyclic compound of claim 1 , wherein R 1 is CH 2 OTBDMS or CH 2 i Pr.

7. The cyclic compound of claim 1 wherein the linear molecule is a peptide.

8. The cyclic compound of claim 1 , wherein the amino terminus amino acid of the peptide is selected from the group consisting of proline and an amino acid with an amino group substituted with NHCH 3 , NHBn, NHCH 2 CH 2 SO 2 Ph or NHCH 2 CH 2 CN.

9. The cyclic compound of claim 1 , wherein the linear molecule is a D- or L-amino acid selected from the group consisting of: alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, selenocysteine, serine, tyrosine, threonine, tryptophan and valine.

10. The cyclic compound of claim 1 , wherein the linear molecule is an alpha-amino acid.

11. The cyclic compound of claim 1 , wherein the linear molecule is a beta-amino acid.

12. The cyclic compound of claim 1 , wherein the linear molecule is a gamma-amino acid.

13. The cyclic compound of claim 1 , wherein R″ is tert-Butyl amide.

14. The cyclic compound of claim 1 , wherein the linear peptide consists of 2 amino acids.

15. The cyclic compound of claim 1 , wherein the linear peptide consists of 3 amino acids.

16. The cyclic compound of claim 1 , wherein the linear peptide consists of 4 amino acids.

17. The cyclic compound of claim 1 , wherein the linear peptide consists of 5 amino acids.

18. The cyclic compound of claim 1 , wherein the linear peptide consists of 6 amino acids.

19. The cyclic compound of claim 1 , wherein the linear peptide consists of 7 amino acids.

20. The cyclic compound of claim 1 , wherein the linear peptide consists of 8 amino acids.

21. The cyclic compound of claim 1 , wherein the linear peptide consists of 9 amino acids.

22. The cyclic compound of claim 1 , wherein the nucleophilic moiety is bonded to XH, wherein X is S.

23. The cyclic compound of claim 1 , wherein R6-H is 7-mercapto-4-methyl-coumarin or thiobenzoic acid.

24. The cyclic compound of claim 1 , wherein if the amino acid molecule is an amino acid then the amino terminus is a primary amino group or a secondary amino group but wherein the amino acid molecule is a linear peptide, then the amino terminus is a secondary amino group.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded May 17, 2023
From: ZOOLANDER SA LLC
To: ZEALAND PHARMA A/S
Reel/Frame 063672/0342 →
RELEASE OF SECURITY INTEREST Recorded May 11, 2023
From: ZOOLANDER SA LLC
To: ZEALAND PHARMA A/S
Reel/Frame 063624/0547 →
PATENT SECURITY AGREEMENT Recorded Dec 27, 2021
From: ZEALAND PHARMA A/S
To: ZOOLANDER SA LLC
Reel/Frame 058593/0261 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2016
From: YUDIN, ANDREI; HILI, RYAN
To: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO
Reel/Frame 037486/0181 →